Episode
Treating AML, Before and After Relapse
- Podcast
- Blood Podcast
- Published
- Jun 18, 2026
- Duration seconds
- 973
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/2dbaa214
Actions
POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/treating-aml-before-and-after-relapse/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-podcast-664776/treating-aml-before-and-after-relapse.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode, Blood editor Dr. Laura Michaelis interviews Drs. Nigel Russell and Uwe Platzbecker on their articles published in volume 147 issue 10 of Blood . Dr. Russell discuses " CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non–adverse-risk AML: the NCRI AML18 trial " where a large randomized trial demonstrated that DA-GO2 provided greater overall survival as compared to CPX-351, and that further studies should compare DA-GO2 to lower-intensity venetoclax-based regimens. Dr. Platzbecker shares insights from the first prospective study to evaluate the clinical impact of early therapeutic intervention for MRD in " Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial " demonstrating potential therapies for patients to achieve and maintain remission.